Eli Lilly and Company
NYSELLY enters the week at $988.87, up 13.1% over five sessions — its sharpest weekly rally in recent memory — as a strong earnings beat on April 30 reset expectations and sent a wave of upward analyst revisions through Wall Street. The earnings reaction tells the story clearly. LLY jumped 13.2% on April 30 after reporting Q1 results, and added another 2.7% on May 4 when a…
LLY short interest surges 20.6% over one week to 0.93% of float, driven by sharp 15.5% single-day spike on April 24th.
Snapshot as of 6 May 2026
A new long-form analysis for LLY this week — anomalies vs the company's own history, peer comparisons, news context, and the full data picture. Premium subscribers only.
Read on ORTEX →Sign up for premiumLLY enters the week at $988.87, up 13.1% over five sessions — its sharpest weekly rally in recent memory — as a strong earnings beat on April 30 reset expectations and sent a wave of upward analyst revisions through…
Eli Lilly heads into its May 4 Q1 report with the stock surging back toward a consensus that still sees meaningful upside from current levels. The standout heading into the print is the price action. Lilly jumped…
Why this matters: Three distinct ORTEX data streams—short interest, cost to borrow, and options sentiment—have simultaneously shifted on LLY in the past week. The convergence comes six days before the pharmaceutical…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for LLY — free to start on ORTEX.
Sign up for free →Open LLY on ORTEX